CEA-Leti to develop nuclear, optical tracer
In collaboration with four French partners, health IT research company CEA-Leti has launched a project to develop a PET tracer incorporating the company’s patented Lipidot nano-carrier, which would function for both pre-operative nuclear imaging and intraoperative optical imaging of cancers.
Aiming at use during ablation and biopsy, the three-year Nano-Eno project will involve the grafting of a peptide molecule that recognizes specific cancers to CEA-Let’s organic nano-carrier Lipidot. The current phase of the project is geared toward demonstrating proof of concept.
CEA-Leti conducts research and develops nanoelectronics and technology for healthcare and is based in Grenoble, France. The Nano-Eno project includes Advanced Accelerator Applications, Fluoptics and VetAgro Sup, all headquartered in the south of France, as well as Frédéric Joliot Hospital in Orsay, outside of Paris.
Aiming at use during ablation and biopsy, the three-year Nano-Eno project will involve the grafting of a peptide molecule that recognizes specific cancers to CEA-Let’s organic nano-carrier Lipidot. The current phase of the project is geared toward demonstrating proof of concept.
CEA-Leti conducts research and develops nanoelectronics and technology for healthcare and is based in Grenoble, France. The Nano-Eno project includes Advanced Accelerator Applications, Fluoptics and VetAgro Sup, all headquartered in the south of France, as well as Frédéric Joliot Hospital in Orsay, outside of Paris.